Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Barriers early in the course of transplantation
- Landmark observations implicating complement
- Compartmentalisation
- Hepatocyte synthesis as complement source
- Extravascular synthesis
- Marking of renal tissue by complement
- Intragraft expression of C3
- Metabolic & physical injury
- C3 hyperexpression in donor kidney biopsy
- C3 deficient mouse donor kidney
- C3a/C5a signalling on resident & infiltrating cells
- Impaired C5b-9 assembly & ischaemic injury
- Summary 1
- Cell mediated rejection
- C3 deficient allografts have long term graft survival
- Donor dendritic cells: complement & MHC II
- C3 deficient mouse dendritic cells
- C3a sensing enhances immunogenicity
- Tolerogenic dendritic cells from C3 deficient mice
- C5a acting directly on T cells & alloimmunity
- C3-coated renal tubule cells
- Summary 2
- Antibody-mediated rejection
- IgG production in skin grafted mice
- Pre-existing antidonor antibodies
- De novo antibodies linked to chronic rejection
- Risk stratification of serum antidonor antibody
- Complement triggering in donor organ
- Complement system pattern recognition pathways
- Collectin-11 expression
- Collectin-11 deficiency
- Fucosylated ligand on hypoxic tubule cells
- Complement deposition on hypoxic tubule cells
- How CL-11 triggers complement activation
- Template for emerging therapeutic strategies
- Messages: complement & transplantation (1)
- Messages: complement & transplantation (2)
- Acknowledgements
Topics Covered
- Important barriers to successful transplantation
- Tissue compartments affected by injury
- Contribution of local synthesis of complement
- C5a and C5b-9 dependent ischaemic renal tubule injury
- Priming of the T cell response by C3a, C5a
- Triggering complement activation on hypoxic cells
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sacks, S. (2018, April 30). Complement and organ transplantation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/RJKY1853.Export Citation (RIS)
Publication History
Financial Disclosures
- Consultancies for industry currently including Alexion, Omeros, and UCB.
Other Talks in the Series: The Complement System
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Steven Sacks,
and I'm a clinical nephrologist with a particular interest in transplantation.
My interest in complement stems from local complement synthesis,
and I want to try and develop some of the ideas
that have sprung up around that particular aspect of cell biology.
0:17
Transplantation has been a highly successful procedure but it's not totally successful.
There are two particular barriers which still hold up
the procedure in terms of long-term outcome.
The first of these is what I've called metabolic and physical injury which
sums up a lot of different stimuli that occurred during the transfer of the organ,
and in particular the kidney,
from the donor to the recipient.
That results in a number of different forms of stress
which are just conveniently labelled as metabolic and physical injury.
The second aspect is a recognition of a donor organ as non-self.
That triggers a series of events which can be summarized into two things,
one is the cell-mediated rejection and the other is antibody-mediated rejection.
Each produces its own form of injury,
that when these are together they
can shorten the half-life of kidney by up to eight years.
In other words, about 50 percent of the grafts are lost by
67 years if both are present together and if neither of those insults are present,
then the kidney last for many years longer,
perhaps about eight or nine years longer than that on average.
1:29
A number of observations have shaped my thoughts about complement.
So these are not necessarily the only observations that could be called
landmark in the history of how complement is linked to transplantation,
but they certainly sparked my interest.
The first truly successful transplant carried out in Boston was in 1954,
and so there was about a 15 year space
before the first real observation linking complement the transplantation was made,
and this was out of Paul Terasaki's laboratory.
They found the presence of antibodies against the donor organ which
when they interacted with the endothelium surface of the donor organ,
led to the activation of the complement cascade and destruction of a transplant.
Within about space of the next 10 years,
further advances had been made so that it became clear that
the complement system was not only a factor of antibody-mediated damage in the organ,
but was important and played an instructive role in priming the antibody response.
These observations came from a series of
elegant studies carried out by Mark Pepys and colleagues,
in Cambridge in the 1970s.
Basically, they found that for non-complement antigen,
so these were experimental antigen models in complement depleted animals.
It was very difficult for the animals to make a fully mature immunoglobulin response.
It was later on that James Marsh working in our laboratory
identified a similar effect in the context
of transplantation which I'll come back to later.
But nonetheless, that was a rather important observation that sparked my interest.
But I was particularly drawn in the 1990s with some seminal observations by Doug Fearon,
and he noticed that the complement system was necessary to
fully mediate a scheme in response in the heart,
so that in the absence of complement and complement treated animals,
the animals were protected from
ischemic injury in coronary artery ligation models for example.
Later, came further insights on chronic rejection which is
the drawn out process by which graft slowly fails towards the end of its life.
This is a very variable phenomena and is
linked to acute rejection also to ischaemic injury.
But nonetheless, the mechanism was unclear and
it was only through studies of complementary position
inside the transplant organ in which were made by Feucht that
new insights were brought about just to the mechanism of chronic rejection.
In other words showing that it was linked to
antibody deposition on the vascular micro capillaries.
My interest really took off before 2002 but the data were published in about 2002,
which were focused on the studies of local complement synthesis.
In the first such study,
it became very clear that if transplantation was carried
out where the donor organ was deficient in complement reduction then,
this led to long-term graft survival.
This actually opened up a whole series of
observations which I'll be coming to a little bit later on.